Prostate Cancer Trial, Recruiting NCT07614256 Sponsor: Guangxi Medical University Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07614256
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are scheduled to have, or have already had, a prostate biopsy or surgical removal of the prostate.
  • People who have already completed standard pre-procedure scans, specifically a multiparametric MRI and a transrectal ultrasound of the prostate.
  • People whose full tissue diagnosis results from their biopsy or surgery are available.
  • People aged between 40 and 90 years.
  • People who are able and willing to sign a written consent form (this applies to those joining the forward-looking part of the study only).

Who may not be able to join:

  • People who have previously had radiation therapy to the pelvic area or have already had their prostate surgically removed.
  • People whose MRI or ultrasound images are incomplete or too poor in quality to be used (for example, due to movement during the scan or missing scan sequences).
  • People who have another separate primary cancer at the same time.
  • People with serious ongoing health conditions that could affect the assessment of the prostate.
  • People whose medical records or tissue diagnosis information are incomplete.
  • People for whom an MRI scan is not safe — for example, due to certain metal implants in the body or severe fear of enclosed spaces (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fubo Wang, MD, Guangxi Medical University

Phone: +86 13677729003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Guangxi Medical University
Registry
ClinicalTrials.gov
Start date
30 May 2025
Est. completion
30 June 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Area Under the Receiver Operating Characteristic Curve (AUC) for predicting clinically significant prostate cancer (csPCa)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov